162 related articles for article (PubMed ID: 38224427)
1. Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors.
Bang AS; Fay CJ; LeBoeuf NR; Etaee F; Leventhal JS; Sibaud V; Arbesman J; Wang JY; Kwong BY
Breast Cancer Res Treat; 2024 Apr; 204(3):643-647. PubMed ID: 38224427
[TBL] [Abstract][Full Text] [Related]
2. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
[TBL] [Abstract][Full Text] [Related]
3. Vitiligo-like lesions induced by cyclin-dependent kinase 4/6 inhibitor Palbociclib: a case report and literature review.
Gao S; Wei G; Hao Y
Pathol Oncol Res; 2023; 29():1611115. PubMed ID: 37483648
[TBL] [Abstract][Full Text] [Related]
4. Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors.
Sollena P; Nikolaou V; Soupos N; Kotteas E; Voudouri D; Stratigos AJ; Fattore D; Annunziata MC; Orlandi A; Di Nardo L; Apalla Z; Deilhes F; Romano MC; Fabbrocini G; Sibaud V; Peris K;
Breast Cancer Res Treat; 2021 Jan; 185(1):247-253. PubMed ID: 32914354
[TBL] [Abstract][Full Text] [Related]
5. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
[TBL] [Abstract][Full Text] [Related]
6. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
[TBL] [Abstract][Full Text] [Related]
7. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor-Positive, ERBB2-Negative Breast Cancer: A Review.
O'Sullivan CC; Clarke R; Goetz MP; Robertson J
JAMA Oncol; 2023 Sep; 9(9):1273-1282. PubMed ID: 37382948
[TBL] [Abstract][Full Text] [Related]
9. Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer.
Kappel C; Elliott MJ; Kumar V; Nadler MB; Desnoyers A; Amir E
Sci Rep; 2024 Feb; 14(1):3129. PubMed ID: 38326452
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
11. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
12. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
13. Cyclin-Dependent Kinase 4/6 Inhibitors Combined With Radiotherapy for Patients With Metastatic Breast Cancer.
Ratosa I; Orazem M; Scoccimarro E; Steinacher M; Dominici L; Aquilano M; Cerbai C; Desideri I; Ribnikar D; Marinko T; Livi L; Meattini I
Clin Breast Cancer; 2020 Dec; 20(6):495-502. PubMed ID: 32622736
[TBL] [Abstract][Full Text] [Related]
14. Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors.
Burne R; Balu S; Guérin A; Bungay R; Sin R; Paul ML
J Med Econ; 2021; 24(1):806-815. PubMed ID: 34098827
[TBL] [Abstract][Full Text] [Related]
15. Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer.
Visani L; Livi L; Ratosa I; Orazem M; Ribnikar D; Saieva C; Becherini C; Salvestrini V; Scoccimarro E; Valzano M; Cerbai C; Desideri I; Bernini M; Orzalesi L; Nori J; Bianchi S; Morandi A; Meattini I
Radiother Oncol; 2022 Dec; 177():40-45. PubMed ID: 36349599
[TBL] [Abstract][Full Text] [Related]
16. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review.
Di Lauro V; Barchiesi G; Martorana F; Zucchini G; Muratore M; Fontanella C; Arpino G; Del Mastro L; Giuliano M; Puglisi F; De Laurentiis M
ESMO Open; 2022 Dec; 7(6):100629. PubMed ID: 36399953
[TBL] [Abstract][Full Text] [Related]
18. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
Schneeweiss A; Ettl J; Lüftner D; Beckmann MW; Belleville E; Fasching PA; Fehm TN; Geberth M; Häberle L; Hadji P; Hartkopf AD; Hielscher C; Huober J; Ruckhäberle E; Janni W; Kolberg HC; Kurbacher CM; Klein E; Lux MP; Müller V; Nabieva N; Overkamp F; Tesch H; Laakmann E; Taran FA; Seitz J; Thomssen C; Untch M; Wimberger P; Wuerstlein R; Volz B; Wallwiener D; Wallwiener M; Brucker SY
Breast; 2020 Dec; 54():88-95. PubMed ID: 32956934
[TBL] [Abstract][Full Text] [Related]
19. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer.
Samuel Eziokwu A; Varella L; Lynn Kruse M; Jia X; Moore HCF; Thomas Budd G; Abraham J; Montero AJ
Clin Breast Cancer; 2021 Jun; 21(3):205-209. PubMed ID: 33189562
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
Kwapisz D
Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
